Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma SA (OTCMKTS:IPHYF) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 4,661 shares, an increase of 9,222.0% from the May 31st total of 50 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days. Currently, 0.0% of the shares of the stock are sold short.

Innate Pharma Stock Performance

Innate Pharma stock opened at $1.65 on Friday. Innate Pharma has a 1 year low of $1.37 and a 1 year high of $2.25. The company’s 50-day moving average is $1.70 and its two-hundred day moving average is $1.89.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.